These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17533496)

  • 1. Infliximab: a novel treatment option for refractory orofacial granulomatosis.
    Peitsch WK; Kemmler N; Goerdt S; Goebeler M
    Acta Derm Venereol; 2007; 87(3):265-6. PubMed ID: 17533496
    [No Abstract]   [Full Text] [Related]  

  • 2. Orofacial granulomatosis as first manifestation of Crohn's disease: successful treatment of both conditions with a combination of infliximab and dapsone.
    Kemmler N; Pfannschmidt N; Strohal R
    Acta Derm Venereol; 2012 Jul; 92(4):406-7. PubMed ID: 22113308
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-TNF-alpha therapy for orofacial granulomatosis: proceed with caution.
    Gaya DR; Aitken S; Fennell J; Satsangi J; Shand AG
    Gut; 2006 Oct; 55(10):1524-5. PubMed ID: 16966709
    [No Abstract]   [Full Text] [Related]  

  • 4. Orofacial granulomatosis: 2 case reports and literature review.
    Kauzman A; Quesnel-Mercier A; Lalonde B
    J Can Dent Assoc; 2006 May; 72(4):325-9. PubMed ID: 16684476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients.
    Josselin L; Mahr A; Cohen P; Pagnoux C; Guaydier-Souquières G; Hayem G; Job-Deslandre C; Liferman F; Pourrat J; Guillevin L
    Ann Rheum Dis; 2008 Sep; 67(9):1343-6. PubMed ID: 18445626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of infliximab therapy in two patients with refractory Vogt-Koyanagi-Harada disease.
    Niccoli L; Nannini C; Cassarà E; Gini G; Lenzetti I; Cantini F
    Br J Ophthalmol; 2009 Nov; 93(11):1553-4. PubMed ID: 19854741
    [No Abstract]   [Full Text] [Related]  

  • 7. Infliximab treatment for resistant Achilles tendonitis.
    Al-Asfar SM; Attar M; Shacfeh H
    Saudi Med J; 2009 Sep; 30(9):1228-30. PubMed ID: 19750273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide in the treatment of refractory orofacial granulomatosis.
    Eustace K; Clowry J; Kirby B; Lally A
    Br J Dermatol; 2014 Aug; 171(2):423-5. PubMed ID: 24601875
    [No Abstract]   [Full Text] [Related]  

  • 9. Common variable immunodeficiency and granulomatosis treated with infliximab.
    Malbrán A; Juri MC; Fernández Romero DS
    Clin Immunol; 2010 Mar; 134(3):359-60. PubMed ID: 20018565
    [No Abstract]   [Full Text] [Related]  

  • 10. [A 74-year old woman with orofacial granulomatosis].
    Goudetsidis L; Titeca G; Poot F
    Rev Med Brux; 2015; 36(3):177-80. PubMed ID: 26372981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab: a promising alternative therapy for refractory arthritis/urethritis/conjunctivitis triad.
    de Carvalho JF; Ribeiro AC; de Moraes JC; Gonçalves C; Goldenstein-Schainberg C; Bonfá E
    Isr Med Assoc J; 2009 Aug; 11(8):511-3. PubMed ID: 19891245
    [No Abstract]   [Full Text] [Related]  

  • 12. [Refractory neurosarcoidosis and infliximab: a growing experience].
    Ritzenthaler T; Gonzalez-Martinez V; Guegen A; Tilikete C; Vighetto A
    Rev Neurol (Paris); 2009 Feb; 165(2):197-200. PubMed ID: 18653204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab.
    Toth C; Martin L; Morrish W; Coutts S; Parney I
    Acta Neurol Scand; 2007 Oct; 116(4):259-62. PubMed ID: 17824906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orofacial Granulomatosis due to Tuberculosis.
    Ramesh V
    Pediatr Dermatol; 2009; 26(1):108-9. PubMed ID: 19250428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescue with infliximab and surgical outcomes for refractory ulcerative colitis.
    Actis GC; Pellicano R; Pinna-Pintor M; Rizzetto M
    J Am Coll Surg; 2007 Oct; 205(4):e3-4. PubMed ID: 17903716
    [No Abstract]   [Full Text] [Related]  

  • 16. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
    Yamamoto-Furusho JK; Uzcanga LF
    Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloidosis secondary to hidradenitis suppurativa. Exceptional response to infliximab.
    Montes-Romero JA; Callejas-Rubio JL; Sánchez-Cano D; González-Martínez FJ; Navas-Parejo A; Ortego-Centeno N
    Eur J Intern Med; 2008 Oct; 19(6):e32-3. PubMed ID: 18848164
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful treatment of refractory Behçet's disease with the TNF-alpha blocker infliximab.
    Jalili A; Kinaciyan T; Barisani T; Peck-Radosavljevic M; Stingl G; Geusau A; Wöhrl S
    Iran J Immunol; 2009 Mar; 6(1):55-8. PubMed ID: 19293479
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of infliximab in ocular inflammation.
    Prendiville C; O'Doherty M; Moriarty P; Cassidy L
    Br J Ophthalmol; 2008 Jun; 92(6):823-5. PubMed ID: 18408083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.